Targeted Strategies for Today's Evolving Markets

MissionIR Blog

VistaGen Therapeutics, Inc. (VSTA) Aligned with World Health Organization’s Global Call for Scaled-Up Response to Mental Disorders

Millions of people around the world suffer from depression, which ranges from short-lived emotional responses to something as severe as suicide, positioning the mental disease as the leading cause of disability worldwide and a dire global health concern.

While recommended depression treatment options range from psychosocial support combined with antidepressant medication or psychotherapy, scientists are seeking new, rapid-acting and more effective treatments than those currently offered in the marketplace.

The World Health Organization (WHO) estimates that globally 350 million people suffer from depression, prompting the organization in 2012 to call for a comprehensive, coordinated response to metal disorders at a country level. The WHO’s Mental Health Gap Action Programme (mhGAP) aims to help countries utilize proper care, psychosocial assistance and medication to increase services for people with mental, neurological and substance abuse disorders.

Here in the states, the U.S. National Institutes of Health (NIH) has conducted clinical trials of ketamine, an FDA-approved anesthetic and adversely used street drug, as a potential antidepressant. While ketamine demonstrates the ability to rapidly alleviate symptoms of depression – compared to current treatments which can take weeks before any therapeutic benefit is achieved – widespread clinical use of ketamine is severely limited due to its high risk for abuse and behavioral impairment, hallucinogenic and schizophrenic-like side effects, and inconvenient intravenous administration in a medical center.

Still, ketamine’s astounding antidepressant benefits have motivated biopharmaceutical companies like VistaGen Therapeutics to aggressively pursue a breakthrough new generation of depression medications.

VistaGen is developing AV-101, a novel, potent and orally- active NMDA receptor (NMDAR) glycine-binding site antagonist. In preclinical studies involving the NIH, AV-101 achieved the fast-acting antidepressant effects of ketamine – but AV-101 greatly differed in that it did not induce the adverse and psychosis-like side effects associated with ketamine and other classic NMDAR channel blockers.

In mid-February 2015, VistaGen broke ground and entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), part of the NIH. Per the CRADA, VistaGen and the NIMH will collaborate on an NIH-sponsored phase 2 clinical study of AV-101 to evaluate the efficacy and safety of the drug candidate in subjects with major depressive disorder (MDD). The study is expected to begin in the first half of this year.

VistaGen isn’t leaving much room for mistakes. The company recently welcomed key opinion leader Gerard Sanacora PhD, MD, professor of Psychiatry at the Yale School of Medicine and director of the Yale Depression Research Program, to its Clinical and Scientific Advisory Board. Dr. Sanacora will collaborate with VistaGen to focus on phase 2 and phase 3 clinical development of AV-101 in MDD.

In addition to depression, VistaGen is also pursuing applications of AV-101 for other indications involving the central nervous system, including chronic neuropathic pain, epilepsy and neurodegenerative diseases such as Parkinson’s and Huntington’s disease. The WHO’s invigorated push for a new approach to depression treatment, however, along with the NIH’s willingness to fully-sponsor the impending Phase 2 clinical study, validates VistaGen’s primary focus of advancing AV-101’s potential as a revolutionary antidepressant for the millions globally who are inadequately served by current medications.

For more information, visit www.vistagen.com

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

Net Element, Inc. (NETE) FY2014 Financial Results Call Scheduled for Tuesday

Global payments technology provider Net Element tomorrow at 2:30 p.m. ET will discuss its operating results for its fiscal year ended December 31, 2014, via conference call. Company Chief Executive Oleg Firer and Chief Financial Officer Jonathan New will lead the call to provide shareholders and interested parties with the company’s operational and financial highlights.

Interested individuals may join the call as a participant or in listen-only mode by dialing into the respective lines below five to 10 minutes prior to the scheduled conference call time.

Conference Call Information

Date: Tuesday, March 31, 2015
Time: 2:30 Eastern Time
Conference ID: 1798030

Participant Toll-Free Dial-In Number: (877) 303-9858
Participant International Dial-In Number: +1 (408) 337-0139

Listen Only Toll-Free Dial-In Number: (800) 514-8534
Listen Only International Dial-In Number: +1 (408) 940-3842

An archive of the call will be available on the investor relations section of Net Element’s website at: http://www.netelement.com/en/ir.

Net Element is a global payments-as-a-service, technology provider with an integrated mobile and transactional services platform serving millions of emerging market clients. The company’s wholly owned subsidiary, TOT Group operates Unified Payments, a U.S.-focused transaction processing and value-added services brand; Aptito, a next generation, cloud-based point of sale payments platform; and TOT Money, a leading mobile payments service provider that has been ranked in the Top 3 mobile payments providers by Beeline, Russia’s second largest telecommunications operator.

For more information, visit www.netelement.com

Posted in Net Element Inc. NETE | Leave a comment

New SEC Rules Provide Smaller Companies Access to Capital, Investors More Choices

Wading through investment options can be an arduous task, but the wide range of choices is exactly what makes the market swell with money-making opportunities. The U.S. Securities and Exchange Commission (SEC) has further widened the spectrum with a set of new rules designed to give smaller companies greater access to capital and, in turn, furnish investors with even more investment choices.

The new rules update and expand Regulation A, an existing exemption from registration for smaller issuers of securities, and implement Title IV of the Jumpstart Our Business Startups (JOBS) Act. The new rules, also referred to as Regulation A+, will be effective 60 days after publication in the Federal Register.

The final rules will enable smaller companies to offer and sell up to $50 million of securities in a 12-month period, subject to eligibility, disclosure and reporting requirements.

“These new rules provide an effective, workable path to raising capital that also provides strong investor protections,” SEC Chair Mary Jo White stated in the news release dated March 25. “It is important for the Commission to continue to look for ways that our rules can facilitate capital-raising by smaller companies.”

Regulation A+ provides for two tiers of offerings:

• Tier 1, for offerings of securities of up to $20 million in a 12-month period, with not more than $6 million in offers by selling security-holders that are affiliates of the issuer;
• Tier 2, for offerings of securities of up to $50 million in a 12-month period, with not more than $15 million in offers by selling security-holders that are affiliates of the issuer.

Both Tiers are subject to certain basic requirements while Tier 2 offerings are also subject to additional disclosure and ongoing reporting requirements.

The exemption would be limited to companies organized in and with their principal place of business in the United States or Canada. The exemption would not apply to businesses that:

• Are already SEC reporting companies and certain investment companies.
• Have no specific business plan or purpose or have indicated their business plan is to engage in a merger or acquisition with an unidentified company.
• Are seeking to offer and sell asset-backed securities or fractional undivided interests in oil, gas or other mineral rights.
• Have been subject to any order of the Commission under Exchange Act Section 12(j) entered within the past five years.
• Have not filed ongoing reports required by the rules during the preceding two years.
• Are disqualified under the “bad actor” disqualification rules.

For more information, read the full release here: http://www.sec.gov/news/pressrelease/2015-49.html

Posted in Small Cap News | Leave a comment

Five Prime Therapeutics, Inc. (FPRX) Takes Leadership Position with Protein Medicines for Life

Protein therapy delivers to the body what it unfortunately lacks in those who possess a variety of illnesses. It is a medical treatment that has extensive healing possibilities currently being developed in many highly visible fields such as cancer and other debilitating diseases.

Today, this medical treatment exhibits great promise for the future as it is, for the most part, still in development and exploratory stages. The concept is similar to yet also unlike gene therapy in that protein therapy delivers protein to the body in specific amounts in the way it would ordinarily present itself to assist in repairing illnesses, treat pain or remake structures. It is important to view what we know today about protein therapy in an investigational context; however researchers and scientists indeed regard it with hope, as early studies have produced numerous benefits in many cases.

Adding to the promise of protein therapy research and development is Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company that has been focusing on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes since 2001.

FPRX’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor. The antibody is in Phase Ib clinical trials aimed at the treatment of rheumatoid arthritis and in pre-IND stage for pigmented villonodular synovitis and several cancers in combination with nivolumab.

Among the company’s numerous other candidates includes its work in the area of immune-oncology. As of late, immuno-oncology has surfaced as one of the most promising and fastest growing areas of cancer research and drug development. FPRX’s protein discovery model is well-suited to identify novel targets for the development of next generation immuno-oncology therapeutics.

Five Prime’s library, made up from more than 100 different human tissues, comprises more than 5,700 structurally complete and biologically active human proteins. The company feels this represents all of the body’s medically important targets for protein therapeutics and is a deep source of potential future protein drugs. Five Prime’s proprietary screening technology enables it to identify ligand and receptor pairs, which is necessary for the treatment of certain diseases at the highest levels.

Five Prime Therapeutics’ exciting progress does not come without pursuit and execution of collaborative agreements with industry leaders. It has a license and collaboration agreement with GlaxoSmithKline LLC, Bristol-Myers Squibb Company and UCB Pharma S.A. Other efforts are made possible with license agreements with Galaxy Biotech LLC, The Regents of the University of California, BioWa, Inc., The Board of Trustees of Leland Stanford Junior University, National Research Council of Canada and Lonza Sales AG.

For more information on the company, visit www.fiveprime.com

Posted in Small Cap News | Leave a comment

Inventergy Global, Inc. (INVT) CEO & Chairman will be Presenting at IPBC Global 2015

Today before the opening bell, Inventergy Global announced that its CEO, Chairman and Founder, Joe Beyers, will be one of the speakers at the IPBC Global 2015, presented by Intellectual Asset Magazine (see http://www.ipbusinesscongress.com/2015). Mr. Beyers will be discusing how to build and maintain a successful licensing-based company, including:

• Understanding the challenges of the licensing landscape
• Building a robust IP portfolio
• Providing insight on new IP related business models

According to the organizers, “IPBC Global is the world’s pre-eminent gathering of senior IP business decision makers. Drawing on the large community of thought leaders based in San Francisco and Silicon Valley, as well those from further afield in the United States and abroad, the 2015 event will offer unrivalled opportunities to discuss cutting-edge issues and network with the people who make the IP weather.”

For more information on Inventergy, an intellectual property (IP) licensing partner specializing in IP value creation, visit www.inventergy.com

Posted in Inventergy Global Inc. INVT | Leave a comment

ENGlobal Corp. (ENG) – Extending Its Reach

ENGlobal provides energy-related engineering and automation services throughout the United States and worldwide. The corporation operates through two business segments – Automation and Engineering – as follows:

- The automation division provides design-, fabrication- and implementation-related services for cutting-edge automation, control, instrumentation and process analytical systems.

- The engineering division provides consulting services for the development, management and execution of projects calling for expert engineering, construction management and associated services. Within this division, ENGlobal also houses its government services group which provides for the management of various government, public sector and international facilities and systems.

Early in March 2015, ENGlobal confirmed the extension of its professional services agreement with Xcel Energy by another five years. Now that this agreement is in place, ENGlobal is expected to continue its ongoing work in all of Xcel Energy’s operating regions, including Colorado, Michigan, Minnesota, New Mexico, North Dakota, South Dakota, Texas and Wisconsin.

Xcel Energy is a major electric and natural gas company. The Minnesota-based company, whose annual revenues are in the $10.9 billion ballpark, delivers a broad portfolio of energy-related products and services to approximately 3.5 million electricity customers and 1.9 million natural gas customers via four operating companies.

ENGlobal and Xcel Energy have an established history of effective collaboration. The two companies have previously united to manage and execute several major capital programs, including the work done on a 60-mile West Main segment pipeline replacement and a 34-mile Cherokee Clean Air – Clean Jobs Act pipeline. They have also collaborated on smaller capital and maintenance jobs like those performed on Xcel Energy’s local gas transmission and distribution network.

ENGlobal anticipates using its Broomfield, Colorado office primarily to support future work on Xcel Energy’s natural gas pipeline and facility projects. The Colorado office is properly staffed with a growing team of project execution professionals who are dedicated to the midstream and downstream energy sectors.

For more information, visit www.englobal.com

Posted in ENGlobal Corp. ENG | Leave a comment

RESAAS Services, Inc. (RSASF) Ushers Modern Social Networking Strategy into Real Estate Industry

The agile convergence of social media and both the personal and business worlds has underhandedly made every user – whether individual, group or organization – a marketer in their own right. This marketing capability has resulted in the creation of ancillary social platforms fields that heavily rely on networking, content creation and knowledge sharing. RESAAS Services, Inc., for example, is a social network structured as an agent-powered real estate industry platform that connects agents and brokers with other like-minded professionals around the world as a tool to gain referral business, attract leads and increase market exposure.

An overwhelming majority of home searches are now conducted online, creating both obstacles and opportunities for agents and brokers looking to grow their business. Traditional forms of attracting homeowners – such as billboards, public benches, newspaper advertising, etc. – are still existent, but typically generate minimal performance and results compared to modern marketing strategies that incorporate the Internet. As such, successful real estate requires agents and brokers to cater to the digital consumer and remain visible and easily accessible to potential clients.

RESAAS founder and CEO Cory Brandolini gained significant networking savvy through 25 years as a commission salesman and more than five years ago set out to use that knowledge to build a platform that would enable like-minded professionals to network online in an unprecedented manner. Incorporated in 2009, RESAAS stands as a first-of-its-kind platform for the real estate industry and now trades on the Canadian Securities Exchange (CSE) under the ticker symbol “RSS” and the OTC Market Group’s OTCQX marketplace under ticker symbol “RSASF.”

“When we look at it on the overall landscape, we’re really in an island on our own on what we’re trying to do. There are other services out there that have similar-type micro-products that that might have a crossover, but really we’re completely on our own in this space,” Brandolini states in an investor-geared corporate video.

View the video in its entirety here: www.corporate.resaas.com/company/investors

Following its commercial launch in 2013, the platform experienced exponential growth, initially tracking user signups on a daily basis – today the company gauges sign-ups per minute. Set in gear for sustainable growth, RESAAS in 2014 turned its focus on creating an industry platform inclusive of third parties, associations and vendors who would enhance industry content and contributions.

The popularity of the platform lies in its ability to address the changing temperament of today’s real estate environment by enabling real estate professionals to build a marketable social profile page, upload and browse listings, share content and information, and ask and answer questions with other industry professionals. The platform is synchronized with Facebook, Twitter and LinkedIn so the user gets more eyes on their inventory and stays connected with agents and brokers around the world.

In essence, RESAAS has harnessed the business-centered power of social media and now channels its momentum toward empowering real estate professionals as content creators and personal and business marketers with a global reach.

For more information, visit www.corporate.resaas.com

Posted in Small Cap News | Leave a comment

Fate Therapeutics, Inc. (FATE) on Course to Address Hematologic Malignancies with PROHEMA®

It’s nearly impossible to list all the ways in which stem cell exploration is important because the usefulness of these cells is virtually limitless. Stem cells have the potential to treat a huge range of diseases and conditions that millions of people around the world suffer from. Their ability to treat so many diseases rests on their unique properties of self-renewal, differentiation and their unspecialized nature.

Fate Therapeutics (NASDAQ: FATE), San Diego, California, is a clinical-stage biopharmaceutical company with a focus on the discovery and development of pharmacologic modulators of adult stem cells to treat severe, life-threatening diseases. It is widely known that adult stem cells play a key role in the growth, maintenance and repair of many tissues and organ systems in the body. As a result of their natural ability to self-renew, and to regenerate and repair diseased or damaged tissue, adult stem cells possess exciting prospects for a myriad of promising applications.

FATE uses the proven pharmacologic modalities of small molecules and targets well-characterized biological mechanisms to program the fate and enhance the therapeutic potential of adult stem cells. The company’s primary product candidate, PROHEMA®, is an ex vivo programmed hematopoietic cellular therapeutic. Today, PROHEMA is in clinical development for patients undergoing hematopoietic stem cell transplantation for the treatment of hematologic malignancies and certain rare genetic disorders. Integral to the company’s focus is the application of its reprogramming modulators to develop human induced pluripotent stem cell-derived cellular therapeutics, and evaluating the in vivo programming of muscle satellite stem cells using its Wnt7a-based protein analogs for muscle regeneration.

The company’s therapeutic programs target innovative mechanisms and are designed to seek out diseases with high degrees of unmet clinical need. As a result of this focus, FATE realizes that it can benefit by working with other companies who bring new ideas and experiences to the drug development market. For this reason, FATE is open to collaborating with potential partners who share its values and drive to advance stem cell science and move closer to developing therapeutics that will ultimately deliver much needed health benefits to those who need them most.

For more information on the company, visit www.fatetherapeutics.com

Posted in Small Cap News | Leave a comment

Align Technology (ALGN) is “One to Watch”

Back in the late 1990′s, the concept of invisible braces being used as an alternative to typical metal wired braces was a hot topic within the specialized branch of dentistry that deals with correcting crooked teeth and improper bites known as orthodontics. By 1997, Zia Chishti, an adult orthodontics patient and Stanford Graduate School of Business graduate who noticed that his plastic retainer held the promise to address this demand, devised an ingenious methodology for implementing invisible braces by using a combination of 3D computer imaging and a series of customized firm, clear plastic retainers designed to incrementally adjust the teeth until the desired dentition (arrangement of the teeth) was obtained. Partnering with some fellow Stanford grads, Chishti formed Align Technology (NASDAQ: ALGN) and set about further developing and commercializing the Invisalign® system to treat a variety of malocclusions, or misalignments of the teeth and dental arches, achieving FDA approval in 1998 and launching the product into markets the following year.

Since then, the company has seen continuously accelerating growth, as brand awareness of their core product spread far and wide across the planet, owing to Invisalign’s comprehensive efficacy for orthodontic treatment, as well as the product’s comfort, ease of use, and the clear aesthetic advantages over unsightly metal braces. The Invisalign system encompasses proprietary virtual modeling software, as well as the related mass customization and rapid manufacturing processes for the virtually clear and easily removable dental aligners, which can include unique features like Power Ridge® and SmartForce® attachments to enhance specific results. The Invisalign system is actually an entire family of products which range from the full treatment option, to highly cost-effective options for minor crowding or spacing. The Invisalign system’s family of products represents an ideal solution for a wide variety of simple, or even complex situations, and is currently prescribed through a network of Invisalign-trained orthodontists and general practitioners (GP) in over 80 countries around the world.

The company has obviously evolved considerably since its inception and today Align Technology offers a wide range of digital treatment solutions tailored to dental industry professionals, including the entry-level, five-stage clear aligner system, Realine®, which is geared towards the GP dentistry market and designed for minor cosmetic fixes, as well as crowding or spacing issues. Realine is distributed exclusively through a partnership (June 2013) with superbly networked health care products and services provider, Henry Schein (NASDAQ:HSIC) and provides non-Invisalign GP dentists with a competitively-priced solution for doing basic corrective work. Product distribution of Realine benefits mightily from HSIC’s enormous reach and the extensive network of long-term and tightly-knit relationships HSIC has developed with some 80k plus dental practitioners worldwide, representing a large, mostly untapped market.

Align Technology enjoys increasingly profitable exposure to a key niche of the roughly $5.4 billion global dental equipment market, which is projected to surge to over $7.1 billion within the next four years, growing at a 5.4% CAGR (Transparency Market Research), via their iTero® Intraoral scanning system. The significant advantages of the iTero scanning system over existing competitors are numerous and include such things as high-res, perfectly focused imaging capabilities which are achievable even if the scanning wand is right up against the patient’s teeth. Unlike competitors, whose scanning technology typically requires the scanning wand to hover five to fifteen millimeters above the teeth in order to stay in focus and produce a good image, making the scanning process a real chore that requires a considerable amount of patience and skill. Scanning with iTero is done quickly and results in highly accurate 3D models (iTero prosthetics enjoy a near-zero rejection rate), meaning that fewer/shorter patient visits are necessary, and that the common occurrence with other approaches of having to redo scans via follow-up appointments is almost completely eliminated. Because the use of messy, uncomfortable and often inaccurate polyvinyl siloxane (or PVS, a silicone elastomer), impression molding is also eliminated, the overall process is much more appealing to patients and dentists/orthodontists are finding they see increased business by being able to offer patients a solution incorporating the iTero scanning system.

Tight iTero integration with Invisalign, as well as the company’s OrthoCAD® digital services, represents another significant advantage for dental professionals. The storage of all associated scanning data in an easily exported file that can be handed off to any laboratory with an open CAD/CAM (computer-aided design and manufacturing) system for completion makes iTero an easy solution to integrate into any existing workflow. Moreover, iTero features like iCast and iRecord, which provide a digital alternative to typical stone-cast models, as well as the architecture’s simplified data storage/retrieval paradigms, vastly improve the overall workflow for already busy practitioners. Since late 2013, the iTero Intraoral Scanner has been fully compatible with the leading chairside design and milling system as well, which is produced by private company E4D and which is exclusively distributed by HSIC. This powerful combination allows clinicians with the iTero scanner to significantly expand services to their patients, offering them fast turnaround options like same-day restorations such as crowns, bridges and veneers. The iTero scanner is a smaller, but important chunk of the overall ALGN story and it represents an important vector for the company to gain increasing access to the $6.5 million plus global dental implant and prosthetics market, where CAD/CAM continues to be a rising star.

CAD/CAM has really revolutionized several aspects of dentistry and has shaved immense amounts of time off procedures like designing dental crowns and bridges, simultaneously leading to vastly improved diagnosis and procedure planning. Align Technology is at the forefront of the CAD/CAM and clear aligner space, with innovative solutions that place the company on an equal or greater footing than other sector operators like Sirona Dental Systems (NASDAQ:SIRO) or Dentsply International (NASDAQ:XRAY). Consolidative forces within the broader industry, like those which led to the acquisition of Swiss dental implant maker, Nobel Biocare, by Danaher Corp. (NYSE:DHR) in late 2014 for some $2.2 billion, make the company’s top-shelf offerings stand out even more. Align has even teamed up with SIRO as of March 2015 to make Sirona’s CEREC Omnicam a valid option for executing Invisalign case submissions, enabling Invisalign providers with a CEREC Omnicam and the related software to simply submit a digital impression instead of the typical PVS impression. ALGN and SIRO also agreed to fully support the sizeable iTero laboratory consumer base with an all-digital workflow. Using Sirona’s inLab software, as of version 15.0, technicians are able to natively import iTero scan data. Comparing the scanning technology, software, services and broad array of aligner offerings from ALGN to relatively less compelling product portfolios from aligner developers like Danaher offshoot, Ormco, with their Simpli5™ express aligner system that is designed only for minor corrections and relapses, makes Align Technology really shine as a one of the sector’s only full-spectrum providers. Especially when you throw in Align’s clearly established practice of going to great lengths in order to cement its platform technologies as the premier choice within the industry by initiating symbiotic partnerships.

The recently upgraded ClinCheck Pro software tool for Invisalign treatment is another big selling point when it comes to the company’s sophisticated digital imaging capabilities, as the software provides extremely precise 3D controls that now make it possible for the first time ever to individually position each tooth right on the 3D model itself and perform design visualization in real-time, leading to better outcomes. Similarly, the company’s Invisalign Outcome Simulator application, which is powered by the iTero scanner, allows doctors to do chairside consultation and visualization directly with the patient, enabling patients to inspect their current dentition right alongside the projected and corrected version, increasing their confidence and ultimately patient retention. The iTero system has quickly become the key leaping off point for many procedures within the industry today and because it is the only scanner on the market with certified milling system and milled model service connectivity, the platform’s multipurpose 3D digital model file and extensive software options have secured its role as the go-to choice for restorations, orthodontics, implant solutions, and 3D case planning procedures in many offices.

Align Technology is constantly developing new iterations of their product line as well and the company’s recent announcement of the launch of their Gen 5 Invisalign developments, engineered specifically for deep bite malocclusion, alongside the rollout of their upgraded ClinCheck Pro software package, shows how the company is constantly eating up new and greater market share. The announcement in March of this year at the highly influential International Dental Show in Cologne, Germany, that the latest edition of their market leading iTero Element Intraoral scanning system has been made available, was met with considerable excitement by the attendees, who no doubt salivated over the significantly improved imaging technology, with 20 times faster scanning speed, improved color scans, and backwards compatibility with older iTero workflows. The backwards compatibility is a prime example of Align’s commitment to satisfying their customer base, which has collectively done over 1.2 million implant scans, over 1.3 million orthodontic scans, and over 600,000 Invisalign scans to date. The newest version of the scanner unit is also much smaller overall, with a more compact form factor and footprint, as well as being considerably lighter. The new unit also features a 40% smaller and lighter scanning wand with built-in controls and an instant defogging system, as well as a 19″ high-def multi-touch display, and integrated gyro capabilities for easily rotating the on-screen models.

Invisalign has risen to prominence in a very short time and is considered by many practitioners in the industry as the Gold Standard of clear aligners. The Invisalign system is generally seen by many in the industry as having so much development time and resources built into the overall platform that it is impossible for others to really compete. Cheaper, less comprehensive alternatives within the global dental consumables market, like ClearCorrect™, only make up a small portion of the total clear aligner niche dominated by Invisalign. The $15 billion plus global dental consumables market was recently projected by Transparency Market Research as being on-track to hit somewhere around $23.8 billion by 2018, growing on a CAGR of approximately 7.1% and Align Technology looks positioned extremely well to capitalize on this growth. Rising aesthetic standards across the globe are a particularly bullish undercurrent here and the 2015 iData Research report on the roughly $600 million APAC dental implant fixture and final abutment market makes a great argument for the future of ALGN. Projected 10% annual growth of this market in coming years, driven by mounting dental health awareness and income levels throughout China, as well as the proliferation of CAD/CAM technology, means the market could triple in size by as early as 2020.

A recent study by the American Dental Association showed that people consistently found a person’s smile to be the most important physical feature, outstripping the body, eyes, and hair. It seems reasonable that the rapidly rising popularity of cosmetic and preventative dentistry in particular will continue to drive the orthodontics equipment and consumables markets in coming years and Baird Equity Research’s RW Baird dental stock index, which beat the S&P 500 in 2013 by 5%, looks to be setting up for another solid year in 2015, as the sector benefits from stable returns in NA, as well as growing revenues from APAC and EMEA (Europe, the Middle East and Africa) markets.

Align Technology recently (March 3) celebrated a major milestone with their 3 millionth Invisalign customer, shortly after having reported superb Q4 and full-year 2014 financials earlier in January, which saw an 11.4% jump in revenues year-over-year to $198.6 million, and over 126k Invisalign cases served. It is worth noting that it took the company 12 years to hit the 1 million customer mark with Invisalign, but only 3 additional years to acquire their next million, and they closed the gap on the third million in just under two years. Invisalign accounted for the lion’s share of 2014 revenues for ALGN, at around 94% of total, with the iTero scanner and services components making up the remainder. Continued strong growth for ALGN in the APAC and EMEA markets, as well as solid baseline results in NA, reinforced by a 16.1% year-over-year increase in global sales among teenagers (who represent roughly one quarter of their overall market), clearly underscores the growing global brand awareness for their core product line.

A considerable portion of the company’s increasing brand presence is likely attributable to their sleek and highly functional web footprint, as well as their enhanced marketing efforts of late focused on the lucrative teen demographic. With some 5.8 million consumers hitting Align’s various sites last year, 650,000 consumers completing their Smile Assessment form and 443,000 plus consumers actively searching for an Invisalign trained practitioner, the company really knows how to ignite a firestorm of interest. The company enjoys a continually expanding social media footprint as well, with 66% growth last year to over 115,000 followers. International web stats were also robust, with over 2 million visitors from the EMEA region and over 760,000 visitors in APAC, driven in large part by successful regional programs and consumer demand targeted campaigning. The company even opened a series of three dedicated flagship clinics in South East Asia, synced up with a PR blitz to inform and entice consumers.

For more information on Align Technology, visit www.aligntech.com

Posted in Ones to Watch | Leave a comment

Bazaarvoice, Inc. (BV) Connects Brands with Buyers

When people talk to each other, they buy stuff. This simple truth has led Bazaarvoice, Inc. (NASDAQ: BV) to help hundreds of millions of shoppers make more informed and confident purchase decisions by creating a place where they can share their opinions, questions and experiences about the brands they love and the products they buy.

Technology has given people more opportunities to connect with products and brands than ever before. Authentic, shopper-generated reviews, for example, are the most trusted and highly utilized source of information when consumers are deciding what to buy. Bazaarvoice harnesses this power, providing proprietary solutions to retailers and brands that can help them drive sales, build customer loyalty and increase profits by gaining first-hand insight into what their customers are saying.

The company’s impressive suite of products allows clients to host genuine online conversations about their brand and products, which provides a conduit for deeper knowledge into what customers really want. Through its Software as a Service (SaaS) model, Bazaarvoice provides the tools needed to transform user-generated content into improvements in marketing, sales, customer service and product development.

The Bazaarvoice suite of applications is a cloud-based, user-generated content engine designed to help brands capture, manage and respond to customer input in order to achieve optimal growth. With five unique applications, brands can reach their target audiences on a more personal, individual basis in order to promote brand loyalty and recognition.

Bazaarvoice Conversations helps encourage people to review products, ask questions, give answers and share stories. Bazaarvoice Connections helps brands respond to shoppers’ questions across a network of leading retail sites. Bazaarvoice Local places authentic service reviews on the sites of local providers. Bazaarvoice Curations increases brand trust and conversion rates by displaying authentic, moderated social content directly on the site of the client’s brand. Bazaarvoice Media uses retail sites to reach shoppers when they are in the buying mood.

The company’s SaaS products take a more modern approach to many of the internet’s most popular promotional tools. In addition to increasing sales and extending brand reach, brands using Bazaarvoice’s revolutionary products are also able to drive site traffic through the use of valuable, customer-written feedback, which serves as SEO content, while simultaneously managing their reputations by actively participating in consumer conversations. In a time where a few bad reviews can be the death of a fledgling brand, the potential benefits of the services of Bazaarvoice are effectively limitless.

Take, for example, the powerful case study involving ecommerce site Overstock.com. While ecommerce sites typically convert around three percent of total traffic into sales, the popular retail destination was able to leverage the power of Bazaarvoice Media to monetize non-converting traffic. By optimizing the value of each and every ad placement and enlisting top-tier advertisers to Overstock.com, Bazaarvoice was able to streamline the ecommerce site’s ad operations and show executives which strategies truly worked.

As the importance of a properly managed web presence continues to grow for brands of all sizes, Bazaarvoice, through its proprietary SaaS tools, has positioned itself at the top of the critical social depth platforms market. With its Bazaarvoice Conversations platform receiving a perfect rating from Forrester Research, Inc., it’s clear to see that the future looks extremely bright for the Austin, Texas-based company.

For more information, visit www.bazaarvoice.com

Posted in Small Cap News | Leave a comment